Study of two drugs for newly diagnosed extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with extensive-stage small cell lung cancer.
- You have not had any prior treatment for this cancer.
- You are able to care for yourself (ECOG score 0 or 1).
- You have at least one tumor outside the brain that can be measured on a scan.
- You do not have untreated or worsening brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different treatments based on the genetic and molecular features of your tumor. It is for people with stage IV small cell lung cancer that has returned after initial chemotherapy.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
This study tests whether a combination of three drugs—teniposide, cisplatin, and serplulimab—can effectively treat extensive-stage small cell lung cancer (a fast-growing type of lung cancer that has spread). Serplulimab is an immunotherapy drug designed to help your immune system fight cancer.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.